Migliorare la gestione clinica dei pazienti affetti dai diversi istotipi di sarcoma

  • Segretario

    Roberta Maestro


  • Coordinatore Clinico

    Paolo Casali


  • Coordinatore Pre Clinico

    Rita Falcioni


Every year in Italy between 3,000 and 3,500 new cases of sarcoma are diagnosed. Sarcoma is a highly aggressive form of cancer with a strong tendency to develop metastases which require invasive procedures that are likely to have a negative impact on the Patient’s quality of life.  Sarcoma accounts for approximately 2% of all cancers, a percentage that tends to increase in the child or young adult population, where it can reach 15%.

Researchers and doctors from the main Italian Institutes for Cancer Patient Care and Research (IRCCS) with specific expertise, together with the Italian Sarcoma Group, are working on the research project of the Sarcoma WG, coordinated by Roberta Maestro from the National Cancer Institute (CRO) in Aviano, an ACC associated institute, to design and activate clinical trials all over Italy. The WG is working towards creating tools that will enable all hospitals throughout the Country to provide an extremely precise diagnosis and, as a consequence, an even more appropriate treatment than what is being delivered today. As regards innovative therapies, which can be identified through the genetic characterization of the pathology, a special oncochip has been used to accurately and precisely detect known and unknown gene fusion products. The use of Next Generation Sequencing (NGS), albeit complex, provides easy-to-read data that is also available for pathological anatomy for routine diagnosis.

The ACC WG provides researchers, from different institutes all over Italy, with a unique and precious opportunity to work together in a team to transfer the findings observed during research in the laboratory to the clinical setting, new knowledge that can be applied in the selection of more effective treatments with far less toxicity.

Il Team

  • Pre Clinici
  • Clinici